六君子汤对终末期肾病合并营养不良患者的补充治疗作用

目的:探讨六君子汤对终末期肾病(ESRD)合并营养不良患者的补充作用。方法:对ESRD合并营养不良48例患者给予六君子汤治疗,每日1剂,分2次服,每次100 ml。30 d为1个疗程,连续观察2个疗程。监测治疗前后白蛋白、前白蛋白、转铁蛋白水平;进行营养评估(SGA);观察患者厌食、乏力及皮肤瘙痒等临床症状的缓解情况。结果:治疗后患者的白蛋白、前白蛋白和转铁蛋白水平有明显提高(P<0.01);治疗前AC、TSF、AMC值均为最小,随着治疗的进展,患者的各项指标均有提高;SGA评分营养不良总发生率降低;患者厌食、乏力症状有改善。结论:在充分透析的同时六君子汤对ESRD合并营养不良患者有较好疗效,可作为补充治疗。     

The First Identification of Encephalitozoon cuniculi Infection in an Animal Care Worker in Turkey

Background:

As a zoonotic pathogen, Encephalitozoon cuniculi is a cause of serious disease in animals and people. The present study was to evaluate the health status examination of this seropositive animal care worker in our previous study.

Methods:

Blood samples were taken from five workers. CIA test was applied to detect antibodies against E. cuniculi in blood serum. The indirect immunofluorescence antibody test was used as confirmation test. Seropositive worker had a complete medical examination.

Results:

Only one worker was found to be seropositive according to the results of the serological test. Sera positive to E. cuniculi was confirmed with IFAT and spores were detected in the urine sample of the worker. The worker was treated with albendazole.

Conclusion:

Rabbits should be examined routinely for the presence of anti-E. cuniculi antibody. People working with laboratory animal should avoid contact with urine and faeces of infected or pay attention to personal hygiene.     

Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy

PurposeBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and poor prognostic hematological malignancy. There is still no standard treatment established for BPDCN patients. We aim to summarize the main clinical, biological features and treatment of 9 BPDCN patients.MethodsNine patients with BPDCN who had been diagnosed between July 2008 and December 2018 in Ankara University School of Medicine, were retrospectively evaluated.ResultsAll patients (n = 9) were male, median age was 64 (21–80). Five patients (55.6%) had bone marrow infiltration, 5 patients (55.6%) cutaneous lesions, 6 patients (66.7%) lymph node involvement, 2 patients (22.2%) central nervous system involvement and 2 patients (22.2%) spleen involvement at time of diagnosis. Complex karyotype was observed in 2 patients. CHOP was given to 5 patients (55.6%), hyper-CVAD to 2 patients (22.2%), fludarabine, cyclophosphamide and mitoxantrone to 1 patient (11.1%) and cyclophosphamide, etoposide, methylprednisolone to 1 patient (11.1%) as first line chemotherapy. Four patients (44.4%) underwent allogeneic hematopoietic stem cell transplantation (AHSCT) in complete remission (CR) 1. Venetoclax was given to a transplant ineligible patient who had skin and lymph node involvement, with the off-label use. The median follow-up time was 15.9 months (3–48.6 months). Estimated median overall survival was 15.9 + 1.6 (95% CI 12.7–19.1) months.ConclusionIntensive induction therapies followed by AHSCT in CR seems to be best approaches for patients with BPDCN. Thus, more effective treatment strategies particularly targeted therapies should be warranted to improve the survival of patients with this rare disease.     

泌尿系感染患者病原菌分布及药敏特征分析

目的分析泌尿系统感染病原菌分布及耐药特征,为临床合理使用抗菌药物提供依据。方法对2011-2012年3 879例尿路感染患者尿培养中分离出的病原菌,采用法国生物梅里埃公司VITEK-2全自动细菌鉴定药敏仪和GN鉴定卡进行菌株鉴定,AST-GN16药敏卡进行药敏试验,并对产ESBLs耐药表型的菌株用双纸片法进行确证。结果 3 879份尿培养标本检出病原菌1 066株,检出率为27.5%;其中革兰阴性菌765株占71.8%,革兰阳性菌215株占20.2%,真菌86株占8.0%,检出率最高的前4位病原菌依次为大肠埃希菌、屎肠球菌、肺炎克雷伯菌和粪肠球菌,分别占51.3%、11.3%、7.6%和5.9%;大肠埃希菌和肺炎克雷伯菌产ESBLs检出率分别为64.4%、64.2%,产ESBLs大肠埃希菌和肺炎克雷伯菌对亚胺培南、美罗培南敏感率较高,>99.0%,对其余抗菌药物敏感率较低,<78.0%;肠球菌属耐药增长迅速。结论泌尿系统感染病原菌以革兰阴性菌为主,大肠埃希菌是主要病原菌,产ESBLs菌检出率较高且呈多药耐药特征,临床上应根据药敏结果合理用药。